A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients
Open Access
- 2 February 2014
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 25 (3), 638-643
- https://doi.org/10.1093/annonc/mdt589
Abstract
In esophageal cancer (EC) patients who are not eligible for surgery, definitive chemoradiation (dCRT) with curative intent using cisplatinum with 5-fluorouracil (5-FU) is the standard chemotherapy regimen. Nowadays carboplatin/paclitaxel is also often used. In this study, we compared survival and toxicity rates between both regimens. This multicenter study included 102 patients treated in five centers in the Northeast Netherlands from 1996 till 2008. Forty-seven patients received cisplatinum/5-FU (75 mg/m2 and 1 g/m2) and 55 patients carboplatin/paclitaxel (AUC2 and 50 mg/m2). Overall survival (OS) was not different between the cisplatinum/5-FU and carboplatin/paclitaxel group {[P = 0.879, hazard ratio (HR) 0.97 [confidence interval (CI) 0.62–1.51]}, with a median survival of 16.1 (CI 11.8–20.5) and 13.8 months (CI 10.8–16.9). Median disease-free survival (DFS) was comparable [P = 0.760, HR 0.93 (CI 0.60–1.45)] between the cisplatinum/5-FU group [11.1 months (CI 6.9–15.3)] and the carboplatin/paclitaxel group [9.7 months (CI 5.1–14.4)]. Groups were comparable except clinical T stage was higher in the carboplatin/paclitaxel group (P = 0.008). High clinical T stage (cT4) was not related to OS and DFS in a univariate analysis (P = 0.250 and P = 0.201). A higher percentage of patients completed the carboplatin/paclitaxel regimen (82% versus 57%, P = 0.010). Hematological and nonhematological toxicity (≥grade 3) in the carboplatin/paclitaxel group (4% and 18%) was significantly lower than in the cisplatinum/5-FU (19% and 38%, P = 0.001). In this study, we showed comparable outcome, in terms of DFS and OS for carboplatin/paclitaxel compared with cisplatinum/5-FU as dCRT treatment in EC patients. Toxicity rates were lower in the carboplatin/paclitaxel group together with higher treatment compliance. Carboplatin/paclitaxel as an alternative treatment of cisplatinum/5-FU is a good candidate regimen for further evaluation.This publication has 14 references indexed in Scilit:
- Chemoradiation for Esophageal CancerAmerican Journal of Clinical Oncology, 2011
- Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysisThe Lancet Oncology, 2011
- Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Continuing Rapid Increase in Esophageal Adenocarcinoma in England and WalesThe American Journal of Gastroenterology, 2008
- Oesophageal cancer in The Netherlands: Increasing incidence and mortality but improving survivalEuropean Journal of Cancer, 2007
- A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal CancerJournal of Thoracic Oncology, 2007
- A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal CancerClinical Cancer Research, 2004
- TNM, sixth edition: New developments in general concepts and rulesSeminars in Surgical Oncology, 2003
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the EsophagusThe New England Journal of Medicine, 1992